

---

By: **Delegate Stern**  
Introduced and read first time: February 13, 2004  
Assigned to: Health and Government Operations

---

A BILL ENTITLED

1 AN ACT concerning

2 **Prescription Drug Distribution Safety Act**

3 FOR the purpose of requiring a wholesale prescription drug distributor to review  
4 certain records for the acquisition of prescription drugs in a certain manner;  
5 requiring a wholesale prescription drug distributor to establish and maintain  
6 certain inventories and records; requiring the records to meet certain  
7 specifications; requiring inventories and records to be made available for  
8 inspection and photocopying by certain officials and for a certain period of time;  
9 requiring a person who is engaged in the wholesale distribution of a prescription  
10 drug and who is not the manufacturer of that drug to provide, at a certain time,  
11 a pedigree paper to the person who receives the drug; establishing requirements  
12 for a pedigree paper; requiring a wholesale prescription drug distributor to  
13 provide the Department of Health and Mental Hygiene with a certain list;  
14 establishing requirements for changes to and confidentiality of the list;  
15 requiring a wholesale prescription drug distributor, prior to a certain purchase,  
16 to enter into a certain agreement, determine certain insurance coverage, obtain  
17 certain information, verify a certain permit, and inspect a certain establishment  
18 for a certain purpose; requiring the Department to conduct certain inspections;  
19 authorizing the Department to take certain actions with regard to the  
20 inspections; authorizing certain property owners to seek judicial relief after a  
21 seizure of prescription drugs; authorizing the Department to close a prescription  
22 drug wholesale establishment under certain circumstances; providing that a  
23 certain refusal constitutes an imminent danger to the public health; authorizing  
24 the Department to issue and serve a complaint upon a permittee under certain  
25 circumstances; providing for a certain hearing; authorizing the Department to  
26 issue a certain cease and desist order under certain circumstances; making  
27 certain actions unlawful; establishing certain penalties for certain violations;  
28 requiring the Department to adopt certain regulations; defining certain terms;  
29 altering certain definitions; and generally relating to distribution of prescription  
30 drugs.

31 BY repealing and reenacting, with amendments,  
32 Article - Health - General  
33 Section 21-201 and 21-216(c)  
34 Annotated Code of Maryland

1 (2000 Replacement Volume and 2003 Supplement)

2 BY repealing and reenacting, without amendments,  
3 Article - Health - General  
4 Section 21-216(a) and (b)  
5 Annotated Code of Maryland  
6 (2000 Replacement Volume and 2003 Supplement)

7 BY adding to  
8 Article - Health - General  
9 Section 21-228, 21-229, 21-229.1, and 21-258.1  
10 Annotated Code of Maryland  
11 (2000 Replacement Volume and 2003 Supplement)

12 BY repealing and reenacting, with amendments,  
13 Article - Health Occupations  
14 Section 12-602(a), (c), and (h)  
15 Annotated Code of Maryland  
16 (2000 Replacement Volume and 2003 Supplement)

17 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF  
18 MARYLAND, That the Laws of Maryland read as follows:

19 **Article - Health - General**

20 21-201.

21 (a) In this subtitle the following words have the meanings indicated.

22 (B) "AUTHENTICATE" MEANS TO AFFIRMATIVELY VERIFY BEFORE ANY  
23 DISTRIBUTION OF A LEGEND DRUG OCCURS THAT EACH TRANSACTION LISTED ON A  
24 PEDIGREE PAPER HAS OCCURRED.

25 (C) "CONTRABAND LEGEND DRUG" MEANS ANY ADULTERATED DRUG, ANY  
26 COUNTERFEIT DRUG, OR ANY LEGEND DRUG FOR WHICH A PEDIGREE PAPER DOES  
27 NOT EXIST, OR FOR WHICH THE PEDIGREE PAPER IN EXISTENCE HAS BEEN FORGED,  
28 COUNTERFEITED, FALSELY CREATED, OR CONTAINS ANY ALTERED, FALSE, OR  
29 MISREPRESENTED MATTER.

30 [(b)] (D) "Counterfeit drug" means a drug that:

31 (1) Bears, or the container or labeling of which bears, without  
32 authorization, the trademark, trade name, imprint, symbol, or any other identifying  
33 mark, or any likeness of any of these markings, of a manufacturer, processor, packer,  
34 or distributor other than the one who, in fact, manufactured, processed, packed, or  
35 distributed the drug; and

1 (2) By use of these markings falsely purports or is represented to be the  
2 product of, or to have been packed or distributed by, the other drug manufacturer,  
3 processor, packer, or distributor.

4 [(c)] (E) (1) "Established name" means, in regard to a drug or an ingredient  
5 of a drug:

6 (i) The name designated under the Federal Act;

7 (ii) If a name has not been designated under the Federal Act, but  
8 the drug or ingredient has been recognized in an official compendium, then the title  
9 used in the compendium; or

10 (iii) If a name cannot be determined under item (i) or (ii) of this  
11 paragraph, the common or usual name of the drug or ingredient.

12 (2) In applying the provisions of paragraph (1)(ii) of this subsection, if a  
13 drug or an ingredient of a drug is recognized in both the United States  
14 Pharmacopoeia and National Formulary and in the Homeopathic Pharmacopoeia of  
15 the United States under different official titles, the title used in the United States  
16 Pharmacopoeia and National Formulary is the established name, unless the drug is  
17 labeled and offered for sale as a homeopathic drug, in which event the official title  
18 used in the Homeopathic Pharmacopoeia of the United States is the established  
19 name.

20 [(d)] (F) "New drug" means any drug that:

21 (1) Among experts qualified by scientific training and experience to  
22 evaluate the safety and effectiveness of drugs, is not recognized generally as safe and  
23 effective for use under the conditions specified, recommended, or suggested in the  
24 labeling of the drug; or

25 (2) As a result of investigations to determine its safety and effectiveness  
26 for use, has become recognized by these experts as safe and effective under the  
27 conditions, but that, other than in the investigations, has not been used to a material  
28 extent or for a material time under the conditions.

29 (G) "PEDIGREE PAPER" MEANS A DOCUMENT APPROVED BY THE  
30 DEPARTMENT CONTAINING INFORMATION THAT RECORDS EACH DISTRIBUTION OF A  
31 LEGEND DRUG, FROM SALE BY A PHARMACEUTICAL MANUFACTURER, THROUGH  
32 ACQUISITION AND SALE BY A WHOLESALER OR REPACKAGER, UNTIL FINAL SALE TO  
33 A PHARMACY OR OTHER PERSON ADMINISTERING OR DISPENSING THE DRUG.

34 [(e)] (H) (1) "Prescription drug" means a drug that, under § 21-220 of this  
35 subtitle, may be dispensed only on the prescription of a health practitioner who is  
36 authorized by law to prescribe the drug.

37 (2) "PRESCRIPTION DRUG" INCLUDES A LEGEND DRUG.

1 (I) (1) "REPACKAGER" MEANS A PERSON WHO REPACKS OR OTHERWISE  
2 CHANGES THE CONTAINER, WRAPPER, OR LABELING TO FURTHER THE  
3 DISTRIBUTION OF A PRESCRIPTION DRUG.

4 (2) "REPACKAGER" DOES NOT INCLUDE A PHARMACY THAT IS  
5 OPERATING IN COMPLIANCE WITH PHARMACY PRACTICE STANDARDS UNDER TITLE  
6 12 OF THE HEALTH OCCUPATIONS ARTICLE.

7 [(f)] (J) "State adopted federal rule or regulation" means any rule or  
8 regulation that is adopted by the federal government under the Federal Act and that  
9 becomes a rule or regulation by automatic adoption under the provisions of this  
10 subtitle.

11 21-216.

12 (a) For purposes of this subtitle, a drug or device is adulterated if the  
13 standards in this section apply.

14 (b) A drug or device is adulterated if:

15 (1) Any part of it is a filthy, putrid, or decomposed substance; or

16 (2) It was produced, prepared, packed, or held under unsanitary  
17 conditions that reasonably would be expected to have:

18 (i) Contaminated it with filth; or

19 (ii) Caused it to be injurious to health.

20 (c) In addition to the grounds specified in subsection (b) of this section, a drug  
21 is adulterated if:

22 (1) Any part of its container is composed of any poisonous or otherwise  
23 deleterious substance that reasonably would be expected to have caused the drug to  
24 be injurious to health;

25 (2) For purposes of coloring only, it is or it contains a color additive, the  
26 particular use of which has not been found safe as provided under § 21-239 of this  
27 subtitle;

28 (3) The mixing or packing of any substance with the drug has reduced  
29 the quality or strength of the drug;

30 (4) Any substance has been substituted for any part of the drug;

31 (5) The methods, facilities, or controls used in the manufacture,  
32 processing, packing, or holding of the drug do not conform to, or are not administered  
33 in conformity to, good practice to assure that the drug:

34 (i) Meets the requirements of this subtitle as to safety; and

1 (ii) Has the identity, strength, quality, and purity that it purports to  
2 have;

3 (6) It is purported to be a drug the name of which is recognized in an  
4 official compendium and:

5 (i) The strength of the drug differs from, or the quality or purity of  
6 the drug falls below, the standard set in the official compendium; and

7 (ii) The difference in strength, quality, or purity is not stated  
8 plainly on its label; [or]

9 (7) Although not purported to be a drug recognized in an official  
10 compendium, the strength of the drug differs from, or the quality or purity of the drug  
11 falls below that which the drug purports to possess; OR

12 (8) IT IS A LEGEND DRUG FOR WHICH THE REQUIRED PEDIGREE PAPER  
13 IS NONEXISTENT, FRAUDULENT, OR INCOMPLETE UNDER THE REQUIREMENTS OF  
14 THIS SUBTITLE, OR THAT HAS BEEN PURCHASED, HELD, SOLD, OR DISTRIBUTED AT  
15 ANY TIME BY A PERSON NOT AUTHORIZED UNDER FEDERAL OR STATE LAW TO DO SO.  
16 21-228.

17 (A) THE DEPARTMENT SHALL ADOPT REGULATIONS FOR THE STORAGE AND  
18 HANDLING OF PRESCRIPTION DRUGS AND FOR THE ESTABLISHMENT AND  
19 MAINTENANCE OF PRESCRIPTION DRUG DISTRIBUTION RECORDS.

20 (B) (1) ON RECEIPT, A WHOLESALE PRESCRIPTION DRUG DISTRIBUTOR  
21 SHALL REVIEW RECORDS REQUIRED UNDER THIS SECTION FOR THE ACQUISITION OF  
22 PRESCRIPTION DRUGS FOR ACCURACY AND COMPLETENESS, CONSIDERING THE  
23 TOTAL FACTS AND CIRCUMSTANCES SURROUNDING THE TRANSACTIONS AND THE  
24 WHOLESALE DISTRIBUTORS INVOLVED.

25 (2) THE WHOLESALE PRESCRIPTION DRUG DISTRIBUTOR'S REVIEW  
26 SHALL INCLUDE AUTHENTICATING EACH TRANSACTION LISTED ON A PEDIGREE  
27 PAPER.

28 (C) (1) A WHOLESALE PRESCRIPTION DRUG DISTRIBUTOR SHALL  
29 ESTABLISH AND MAINTAIN INVENTORIES AND RECORDS OF ALL TRANSACTIONS  
30 REGARDING THE RECEIPT AND DISTRIBUTION OR OTHER DISPOSITION OF  
31 PRESCRIPTION DRUGS.

32 (2) THE RECORDS SHALL:

33 (I) PROVIDE A COMPLETE AUDIT TRAIL FROM RECEIPT TO SALE OR  
34 OTHER DISPOSITION;

35 (II) BE READILY RETRIEVABLE FOR INSPECTION; AND

36 (III) INCLUDE, AT A MINIMUM, THE FOLLOWING INFORMATION:





1 ARE DETERMINED TO BE COUNTERFEIT OR TO HAVE BEEN DISTRIBUTED IN  
2 VIOLATION OF ANY FEDERAL OR STATE LAW GOVERNING THE DISTRIBUTION OF  
3 DRUGS;

4 (II) DETERMINE THAT THE SELLING WHOLESALE PRESCRIPTION  
5 DRUG DISTRIBUTOR HAS INSURANCE COVERAGE OF NOT LESS THAN THE GREATER  
6 OF 1% OF THE AMOUNT OF ITS TOTAL DOLLAR VOLUME OF PRESCRIPTION DRUG  
7 SALES OR \$500,000, PROVIDED THAT THE COVERAGE NEED NOT EXCEED \$2,000,000;

8 (III) OBTAIN INFORMATION FROM THE SELLING WHOLESALE  
9 PRESCRIPTION DRUG DISTRIBUTOR, INCLUDING:

10 1. THE LENGTH OF TIME THE SELLING WHOLESALE  
11 PRESCRIPTION DRUG DISTRIBUTOR HAS BEEN LICENSED IN THE STATE;

12 2. A COPY OF THE SELLING WHOLESALE PRESCRIPTION  
13 DRUG DISTRIBUTOR'S LICENSES OR PERMITS; AND

14 3. BACKGROUND INFORMATION CONCERNING THE  
15 OWNERSHIP OF THE SELLING WHOLESALE PRESCRIPTION DRUG DISTRIBUTOR,  
16 INCLUDING THE EXPERIENCE OF THE WHOLESALE PRESCRIPTION DRUG  
17 DISTRIBUTOR IN THE WHOLESALE DISTRIBUTION OF PRESCRIPTION DRUGS;

18 (IV) VERIFY THAT THE PERMIT ISSUED BY THE STATE TO THE  
19 SELLING WHOLESALE PRESCRIPTION DRUG DISTRIBUTOR IS VALID; AND

20 (V) INSPECT THE SELLING WHOLESALE PRESCRIPTION DRUG  
21 DISTRIBUTOR'S ESTABLISHMENT TO DOCUMENT THAT IT HAS A POLICIES AND  
22 PROCEDURES MANUAL RELATING TO THE DISTRIBUTION OF DRUGS, THE  
23 APPROPRIATE TEMPERATURE-CONTROLLED ENVIRONMENT FOR DRUGS REQUIRING  
24 TEMPERATURE CONTROL, AN ALARM SYSTEM, APPROPRIATE ACCESS RESTRICTIONS,  
25 AND PROCEDURES TO ENSURE THAT RECORDS RELATED TO THE WHOLESALE  
26 DISTRIBUTION OF PRESCRIPTION DRUGS ARE MAINTAINED AS REQUIRED BY LAW  
27 AND REGULATION.

28 (2) THE INSPECTION REQUIRED UNDER PARAGRAPH (1)(V) OF THIS  
29 SUBSECTION SHALL BE MADE OR CAUSED TO BE MADE BY THE PURCHASING  
30 PRESCRIPTION DRUG DISTRIBUTOR:

31 (I) BEFORE THE PURCHASING PRESCRIPTION DRUG DISTRIBUTOR  
32 PURCHASES ANY DRUG FROM THE SELLING WHOLESALE PRESCRIPTION DRUG  
33 DISTRIBUTOR; AND

34 (II) AT LEAST ONCE EACH YEAR, EITHER BY THE PURCHASING  
35 WHOLESALE PRESCRIPTION DRUG DISTRIBUTOR CONDUCTING A PHYSICAL  
36 INSPECTION OR OBTAINING A COMPLETE COPY OF THE MOST RECENT INSPECTION  
37 REPORT FOR THE ESTABLISHMENT PREPARED BY THE DEPARTMENT OR THE  
38 REGULATORY AUTHORITY RESPONSIBLE FOR WHOLESALE PRESCRIPTION DRUG  
39 DISTRIBUTORS IN THE STATE IN WHICH THE ESTABLISHMENT IS LOCATED.

1 21-229.

2 (A) (1) THE DEPARTMENT SHALL INSPECT EACH WHOLESAL  
3 PRESCRIPTION DRUG ESTABLISHMENT, PRESCRIPTION DRUG REPACKAGER  
4 ESTABLISHMENT, AND RETAIL PHARMACY DRUG ESTABLISHMENT THAT IS  
5 REQUIRED TO HOLD A PERMIT UNDER TITLE 12 OF THE HEALTH OCCUPATIONS  
6 ARTICLE AS OFTEN AS NECESSARY TO ENSURE COMPLIANCE WITH APPLICABLE  
7 LAWS AND RULES.

8 (2) THE DEPARTMENT SHALL HAVE THE RIGHT OF ENTRY AND ACCESS  
9 TO THE FACILITIES UNDER PARAGRAPH (1) OF THIS SUBSECTION AT ANY  
10 REASONABLE TIME.

11 (B) (1) TO PROTECT THE PUBLIC FROM PRESCRIPTION DRUGS THAT ARE  
12 ADULTERATED OR OTHERWISE UNFIT FOR HUMAN CONSUMPTION, THE  
13 DEPARTMENT MAY EXAMINE, SAMPLE, SEIZE, AND STOP THE SALE OR USE OF  
14 PRESCRIPTION DRUGS TO DETERMINE THE CONDITION OF THOSE DRUGS.

15 (2) THE DEPARTMENT MAY IMMEDIATELY SEIZE AND REMOVE ANY  
16 PRESCRIPTION DRUGS IF THE SECRETARY OR THE SECRETARY'S DESIGNEE  
17 DETERMINES THAT THE PRESCRIPTION DRUGS REPRESENT A THREAT TO THE  
18 PUBLIC HEALTH.

19 (3) THE OWNER OF ANY PROPERTY SEIZED UNDER THIS SECTION MAY,  
20 WITHIN 10 DAYS AFTER THE SEIZURE, APPLY TO A COURT OF COMPETENT  
21 JURISDICTION FOR WHATEVER RELIEF IS APPROPRIATE.

22 (4) AT ANY TIME AFTER 10 DAYS, THE DEPARTMENT MAY DESTROY THE  
23 DRUGS AS CONTRABAND.

24 (C) (1) THE DEPARTMENT MAY DETERMINE THAT A PRESCRIPTION DRUG  
25 WHOLESAL ESTABLISHMENT, PRESCRIPTION DRUG REPACKAGER ESTABLISHMENT,  
26 OR RETAIL PHARMACY DRUG ESTABLISHMENT THAT IS REQUIRED TO HAVE A  
27 PERMIT UNDER TITLE 12 OF THE HEALTH OCCUPATIONS ARTICLE IS AN IMMINENT  
28 DANGER TO THE PUBLIC HEALTH AND REQUIRE ITS IMMEDIATE CLOSURE IF THE  
29 ESTABLISHMENT:

30 (I) FAILS TO COMPLY WITH APPLICABLE LAWS AND REGULATIONS;  
31 AND

32 (II) AS A RESULT OF THAT FAILURE, PRESENTS AN IMMINENT  
33 THREAT TO THE PUBLIC'S HEALTH, SAFETY, OR WELFARE.

34 (2) AN ESTABLISHMENT CLOSED UNDER PARAGRAPH (1) OF THIS  
35 SUBSECTION SHALL REMAIN CLOSED UNTIL ALLOWED BY THE DEPARTMENT OR BY  
36 JUDICIAL ORDER TO REOPEN.

37 (D) A REFUSAL TO ALLOW ENTRY TO THE DEPARTMENT FOR INSPECTION AT  
38 REASONABLE TIMES OR A FAILURE OR REFUSAL TO PROVIDE THE DEPARTMENT

1 WITH REQUIRED DOCUMENTATION FOR PURPOSES OF INSPECTION CONSTITUTES AN  
2 IMMINENT DANGER TO THE PUBLIC HEALTH.

3 21-229.1.

4 (A) IN THIS SECTION, "PERMITTEE" MEANS ANY PERSON HOLDING A  
5 WHOLESALE DISTRIBUTION PERMIT ISSUED UNDER § 12-602 OF THE HEALTH  
6 OCCUPATIONS ARTICLE.

7 (B) (1) IN ADDITION TO ANY AUTHORITY OTHERWISE PROVIDED IN THIS  
8 SUBTITLE, THE DEPARTMENT MAY ISSUE AND SERVE A COMPLAINT STATING  
9 CHARGES UPON ANY PERMITTEE WHENEVER THE DEPARTMENT HAS REASONABLE  
10 CAUSE TO BELIEVE THAT THE PERMITTEE IS ENGAGING IN OR HAS ENGAGED IN  
11 CONDUCT THAT IS:

12 (I) 1. AN ACT THAT DEMONSTRATES A LACK OF FITNESS OR  
13 TRUSTWORTHINESS TO ENGAGE IN THE BUSINESS AUTHORIZED UNDER THE  
14 PERSON'S PERMIT;

15 2. HAZARDOUS TO THE PUBLIC HEALTH; OR

16 3. A BUSINESS OPERATION THAT IS A DETRIMENT TO THE  
17 PUBLIC HEALTH;

18 (II) A VIOLATION OF ANY PROVISION OF THIS SUBTITLE;

19 (III) A VIOLATION OF ANY REGULATION OF THE DEPARTMENT;

20 (IV) A VIOLATION OF ANY ORDER OF THE DEPARTMENT; OR

21 (V) A BREACH OF ANY WRITTEN AGREEMENT WITH THE  
22 DEPARTMENT.

23 (2) THE COMPLAINT SHALL CONTAIN A STATEMENT OF FACTS AND  
24 NOTICE OF THE OPPORTUNITY FOR A HEARING IN ACCORDANCE WITH TITLE 10 OF  
25 THE STATE GOVERNMENT ARTICLE.

26 (3) IF A HEARING IS NOT REQUESTED WITHIN THE TIME ALLOWED  
27 UNDER TITLE 10 OF THE STATE GOVERNMENT ARTICLE, OR IF A HEARING IS HELD  
28 AND THE DEPARTMENT FINDS THAT ANY OF THE CHARGES ARE PROVEN, THE  
29 DEPARTMENT MAY ENTER AN ORDER DIRECTING THE PERMITTEE NAMED IN THE  
30 COMPLAINT TO CEASE AND DESIST FROM ENGAGING IN THE CONDUCT IN THE  
31 COMPLAINT AND TAKE CORRECTIVE ACTION TO REMEDY THE EFFECTS OF PAST  
32 IMPROPER CONDUCT AND ASSURE FUTURE COMPLIANCE.

33 (4) (I) A CONTESTED OR DEFAULT CEASE AND DESIST ORDER IS  
34 EFFECTIVE WHEN SERVED ON THE PERMITTEE.

35 (II) AN UNCONTESTED CEASE AND DESIST ORDER IS EFFECTIVE AS  
36 AGREED BETWEEN THE PERMITTEE AND THE DEPARTMENT.

1 (5) (I) WHENEVER THE DEPARTMENT FINDS THAT CONDUCT  
2 DESCRIBED IN PARAGRAPH (1) OF THIS SUBSECTION IS LIKELY TO CAUSE AN  
3 IMMEDIATE THREAT TO THE PUBLIC HEALTH, THE DEPARTMENT MAY ISSUE AN  
4 EMERGENCY CEASE AND DESIST ORDER REQUIRING THE PERMITTEE TO  
5 IMMEDIATELY CEASE AND DESIST FROM ENGAGING IN THE CONDUCT IN THE  
6 COMPLAINT AND TO TAKE CORRECTIVE AND REMEDIAL ACTION.

7 (II) THE EMERGENCY ORDER IS EFFECTIVE IMMEDIATELY ON  
8 SERVICE OF A COPY OF THE ORDER ON THE PERMITTEE AND REMAINS EFFECTIVE  
9 FOR 90 DAYS.

10 (III) IF THE DEPARTMENT BEGINS NONEMERGENCY CEASE AND  
11 DESIST PROCEEDINGS UNDER THIS SUBSECTION, THE EMERGENCY ORDER REMAINS  
12 EFFECTIVE UNTIL THE CONCLUSION OF THE PROCEEDINGS UNDER TITLE 10 OF THE  
13 STATE GOVERNMENT ARTICLE.

14 21-258.1.

15 (A) IT IS UNLAWFUL FOR A PERSON:

16 (1) (I) TO PURCHASE OR SELL PRESCRIPTION DRUGS FOR WHOLESALE  
17 DISTRIBUTION IN EXCHANGE FOR CURRENCY;

18 (II) OTHER THAN A MANUFACTURER, ENGAGED IN THE  
19 WHOLESALE DISTRIBUTION OF LEGEND DRUGS, TO FAIL TO DELIVER TO ANOTHER  
20 PERSON COMPLETE AND ACCURATE PEDIGREE PAPERS CONCERNING A LEGEND  
21 DRUG OR CONTRABAND LEGEND DRUG PRIOR TO TRANSFERRING THE LEGEND DRUG  
22 OR CONTRABAND LEGEND DRUG TO ANOTHER PERSON;

23 (III) ENGAGED IN THE WHOLESALE DISTRIBUTION OF LEGEND  
24 DRUGS TO FAIL TO ACQUIRE COMPLETE AND ACCURATE PEDIGREE PAPERS  
25 CONCERNING A LEGEND DRUG OR CONTRABAND LEGEND DRUG PRIOR TO  
26 OBTAINING THE LEGEND DRUG OR CONTRABAND LEGEND DRUG FROM ANOTHER  
27 PERSON; OR

28 (IV) TO KNOWINGLY DESTROY, ALTER, CONCEAL, OR FAIL TO  
29 MAINTAIN COMPLETE AND ACCURATE PEDIGREE PAPERS CONCERNING ANY  
30 LEGEND DRUG OR CONTRABAND LEGEND DRUG IN THE PERSON'S POSSESSION; OR

31 (2) ON OR AFTER JULY 1, 2007:

32 (I) ENGAGED IN THE WHOLESALE DISTRIBUTION OF LEGEND  
33 DRUGS WHO IS IN POSSESSION OF PEDIGREE PAPERS CONCERNING LEGEND DRUGS  
34 OR CONTRABAND LEGEND DRUGS, TO FAIL TO AUTHENTICATE THE MATTERS  
35 CONTAINED IN THE PEDIGREE PAPERS AND TO NEVERTHELESS ATTEMPT TO  
36 FURTHER DISTRIBUTE LEGEND DRUGS OR CONTRABAND LEGEND DRUGS; OR

37 (II) IN POSSESSION OF PEDIGREE PAPERS CONCERNING LEGEND  
38 DRUGS OR CONTRABAND LEGEND DRUGS, TO FALSELY SWEAR OR CERTIFY THAT THE  
39 PERSON HAS AUTHENTICATED THE MATTERS CONTAINED IN THE PEDIGREE PAPERS.

1 (B) A PERSON WHO VIOLATES ANY PROVISION OF SUBSECTION (A) OF THIS  
2 SECTION IS GUILTY OF A FELONY AND ON CONVICTION IS SUBJECT TO:

3 (1) A FINE NOT EXCEEDING \$10,000 OR IMPRISONMENT NOT EXCEEDING  
4 3 YEARS OR BOTH; OR

5 (2) IF THE PERSON HAS BEEN CONVICTED ONCE OF VIOLATING  
6 SUBSECTION (B) OF THIS SECTION, A FINE NOT EXCEEDING \$25,000 OR  
7 IMPRISONMENT NOT EXCEEDING 5 YEARS OR BOTH.

8 (C) IT IS UNLAWFUL FOR A PERSON TO:

9 (1) REMOVE A PHARMACY'S DISPENSING LABEL FROM A DISPENSED  
10 PRESCRIPTION DRUG WITH THE INTENT TO FURTHER DISTRIBUTE THE  
11 PRESCRIPTION DRUG;

12 (2) DISTRIBUTE A PRESCRIPTION DRUG THAT WAS PREVIOUSLY  
13 DISPENSED BY A LICENSED PHARMACY, UNLESS SUCH DISTRIBUTION WAS  
14 AUTHORIZED BY LAW;

15 (3) KNOWINGLY FORGE, COUNTERFEIT, OR FALSELY CREATE ANY  
16 PEDIGREE PAPER, FALSELY REPRESENT ANY FACTUAL MATTER CONTAINED ON ANY  
17 PEDIGREE PAPER, OR KNOWINGLY OMIT TO RECORD MATERIAL INFORMATION  
18 REQUIRED TO BE RECORDED IN A PEDIGREE PAPER;

19 (4) KNOWINGLY PURCHASE OR RECEIVE A LEGEND DRUG IN A  
20 WHOLESALE DISTRIBUTION TRANSACTION FROM A PERSON NOT AUTHORIZED TO  
21 DISTRIBUTE LEGEND DRUGS UNDER TITLE 12 OF THE HEALTH OCCUPATIONS  
22 ARTICLE;

23 (5) KNOWINGLY SELL OR TRANSFER A LEGEND DRUG IN A WHOLESALE  
24 DISTRIBUTION TRANSACTION TO A PERSON NOT AUTHORIZED TO PURCHASE OR  
25 POSSESS LEGEND DRUGS UNDER THE LAW OF THE JURISDICTION IN WHICH THE  
26 PERSON RECEIVES THE DRUG;

27 (6) BE KNOWINGLY IN ACTUAL OR CONSTRUCTIVE POSSESSION OF ANY  
28 AMOUNT OF CONTRABAND LEGEND DRUGS, KNOWINGLY SELL OR DELIVER, OR  
29 POSSESS WITH INTENT TO SELL OR DELIVER ANY AMOUNT OF CONTRABAND  
30 LEGEND DRUGS; OR

31 (7) KNOWINGLY FORGE, COUNTERFEIT, OR FALSELY CREATE ANY  
32 PRESCRIPTION LABEL OR LEGEND DRUG LABEL, OR FALSELY REPRESENT ANY  
33 FACTUAL MATTER CONTAINED ON ANY PRESCRIPTION LABEL OR LEGEND DRUG  
34 LABEL.

35 (D) A PERSON WHO VIOLATES ANY PROVISION OF SUBSECTION (C) OF THIS  
36 SECTION IS GUILTY OF A FELONY AND ON CONVICTION IS SUBJECT TO:

37 (1) A FINE NOT EXCEEDING \$10,000 OR IMPRISONMENT NOT EXCEEDING  
38 5 YEARS OR BOTH; OR

1 (2) IF THE PERSON HAS BEEN CONVICTED ONCE OF VIOLATING  
2 SUBSECTION (D) OF THIS SECTION, A FINE NOT EXCEEDING \$25,000 OR  
3 IMPRISONMENT NOT EXCEEDING 10 YEARS OR BOTH.

4 (E) (1) IT IS UNLAWFUL FOR A PERSON TO KNOWINGLY SELL, PURCHASE,  
5 MANUFACTURE, DELIVER, OR BRING INTO THE STATE, OR BE KNOWINGLY IN  
6 POSSESSION OF ANY AMOUNT OF CONTRABAND LEGEND DRUGS VALUED AT \$25,000  
7 OR MORE.

8 (2) A PERSON WHO VIOLATES ANY PROVISION OF PARAGRAPH (1) OF  
9 THIS SUBSECTION IS GUILTY OF A FELONY AND, ON CONVICTION, SHALL PAY A  
10 MANDATORY FINE ACCORDING TO THE FOLLOWING SCHEDULE:

11 (I) IF THE VALUE OF CONTRABAND LEGEND DRUGS INVOLVED IS  
12 AT LEAST \$25,000 BUT LESS THAN \$100,000, THE PERSON SHALL PAY A MANDATORY  
13 FINE OF \$25,000;

14 (II) IF THE VALUE OF CONTRABAND LEGEND DRUGS INVOLVED IS  
15 AT LEAST \$100,000 BUT LESS THAN \$250,000, THE PERSON SHALL PAY A MANDATORY  
16 FINE OF \$100,000; OR

17 (III) IF THE VALUE OF CONTRABAND LEGEND DRUGS INVOLVED IS  
18 \$250,000 OR MORE, THE PERSON SHALL PAY A MANDATORY FINE OF \$200,000.

19 (F) A PERSON WHO KNOWINGLY SELLS, PURCHASES, MANUFACTURES,  
20 DELIVERS, OR BRINGS INTO THE STATE, OR WHO IS KNOWINGLY IN POSSESSION OF  
21 ANY AMOUNT OF CONTRABAND LEGEND DRUGS, AND WHOSE ACTS IN VIOLATION OF  
22 THIS SECTION RESULT IN GREAT BODILY HARM TO A PERSON, IS GUILTY OF A  
23 FELONY AND, ON CONVICTION, IS SUBJECT TO IMPRISONMENT NOT EXCEEDING 30  
24 YEARS.

25 (G) A PERSON WHO KNOWINGLY SELLS, PURCHASES, MANUFACTURES,  
26 DELIVERS, OR BRINGS INTO THE STATE, OR WHO IS KNOWINGLY IN POSSESSION OF  
27 ANY AMOUNT OF CONTRABAND LEGEND DRUGS, AND WHOSE ACTS IN VIOLATION OF  
28 THIS SECTION RESULT IN THE DEATH OF A PERSON IS GUILTY OF A FELONY AND, ON  
29 CONVICTION, IS SUBJECT TO IMPRISONMENT FOR A TERM OF YEARS NOT  
30 EXCEEDING LIFE.

31 **Article - Health Occupations**

32 12-602.

33 (a) (1) In this section, the following words have the meanings indicated.

34 (2) "Distribution permit" means a permit issued by the Board under this  
35 section to:

36 (I) [distribute] DISTRIBUTE prescription drugs or devices into, out  
37 of, or within the State as a distributor, jobber, manufacturer, or wholesaler, wherever  
38 located; OR

1 (II) REPACKAGE PRESCRIPTION DRUGS OR DEVICES.

2 (3) "Prescription drugs or devices" means any drug or device that,  
3 because of its toxicity or other potential for harmful effect, the method of its use, or  
4 the collateral measures necessary for its use, is required by federal law to bear a  
5 cautionary label warning against dispensing without a prescription or is designated  
6 by the Department as not safe for use except under the supervision of a practitioner  
7 licensed to administer drugs or devices of this nature.

8 (c) A person shall hold a distribution permit issued by the Board before the  
9 person may:

10 (1) [distribute] DISTRIBUTE prescription drugs or devices as a  
11 distributor, jobber, manufacturer, or wholesaler; OR

12 (2) REPACKAGE PRESCRIPTION DRUGS OR DEVICES.

13 (h) A distribution permit issued under this section authorizes, WHILE THE  
14 DISTRIBUTION PERMIT IS EFFECTIVE, the distribution permit holder to:

15 (1) [distribute] DISTRIBUTE prescription drugs or devices as a  
16 distributor, jobber, manufacturer, or wholesaler [while the distribution permit is  
17 effective]; OR

18 (2) REPACKAGE PRESCRIPTION DRUGS OR DEVICES.

19 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect  
20 October 1, 2004.